EXEL

Over the past six months, Exelixis's stock price increased by 54.72% between September 10, 2025, and September 9, 2026, with a 52-week range of $33.76 to $59.72. Recent events include a three-month FDA review extension for the zanzalintinib plus atezolizumab New Drug Application for metastatic colorectal cancer, detailed results from the Phase 3 STELLAR-303 trial for zanzalintinib, and subgroup analysis results from the Phase 3 CABINET trial for CABOMETYX. Additionally, there have been announcements regarding patent litigation trial appeals with MSN Laboratories and several shareholder investigations.